Indication:Idiopathic Pulmonary Fibrosis (IPF).
NICE TA379 states: Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis, only if:
* the person has a forced vital capacity (FVC) between 50% and 80% of predicted
* the company provides nintedanib with the discount agreed in the patient access scheme and
* treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12?month period.
NICE technology appraisal guidance [TA347]
Nintedanib, in combination with docetaxel, for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer. Full guidance available at: http://www.nice.org.uk/guidance/ta347/resources/guidance-nintedanib-for-previously-treated-locally-advanced-metastatic-or-locally-recurrent-nonsmallcell-lung-cancer-pdf